Carbonic anhydrase enzymes Ⅱ, Ⅶ, Ⅸ and Ⅻ in colorectal carcinomas

AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against C...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 22; no. 36; pp. 8168 - 8177
Main Authors Viikilä, Pia, Kivelä, Antti J, Mustonen, Harri, Koskensalo, Selja, Waheed, Abdul, Sly, William S, Doisy, Edward A, Pastorek, Jaromir, Pastorekova, Silvia, Parkkila, Seppo, Haglund, Caj
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 28.09.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:AIM To investigate expression of four alpha-carbonic anhydrases(CAs) in colorectal carcinomas(CRC) and compare the results with patients’ survival.METHODS Colorectal carcinoma samples from 539 CRC patients and control tissues were arranged as tissue microarrays and analyzed with antibodies against CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA Ⅻ. Intensity and extent of staining were both scored from 0 to 3 in each sample. These enzyme expression levels were then correlated to patients’ survival and clinicopathological parameters, which were tumor differentiation grade and stage, site of tumor, patients’ age, and gender. Kaplan-Meier analysis and Cox regression hazard ratio model were used to analyze survival data. RESULTS CA Ⅱ and CA Ⅻ staining intensities correlated with patients’ survival in that higher expression indicated poorer prognosis. In Cox regression analysis one unit increase in the CA Ⅱ intensity increased the hazard ratio to 1.19 fold(CI: 1.04-1.37, P = 0.009). A significant correlation was also found when comparing CA Ⅻ staining intensity with survival of CRC patients(HR = 1.18, 95%CI: 1.01-1.38, P = 0.036). The extent of CA Ⅻ immunostaining did not correlate to the patients’ survival(P = 0.242, Kaplan-Meier analysis). A significant interaction between age group and extent of the CA Ⅱ staining was found. Increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older(1.42, 95%CI: 1.16-1.73, P = 0.0006). No correlations were found between CA Ⅶ(intensity P = 0.566, extent P = 0.495, Kaplan-Meier analysis), or CA Ⅸ(intensity P = 0.879, extent P = 0.315, KaplanMeier analysis) immunostaining results and survival, or the other parameters. CONCLUSION The present findings indicate that CA Ⅱ and CA Ⅻ could be useful in predicting survival in CRC.
Bibliography:Pia Viikil?;Antti J Kivel?;Harri Mustonen;Selja Koskensalo;Abdul Waheed;William S Sly;Jaromir Pastorek;Silvia Pastorekova;Seppo Parkkila;Caj Haglund;School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital;Department of Surgery, University of Helsinki and Helsinki University Hospital;Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine;Centre of Molecular Medicine, Institute of Virology, Slovak Academy of Sciences;Research Programs Unit, Translational Cancer Biology, University of Helsinki
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence to: Pia Viikilä, MD, School of Medicine, University of Tampere and Fimlab Ltd, Tampere University Hospital, Medisiinarinkatu 3, 33014 Tampere, Finland. viikila.pia.m@student.uta.fi
Author contributions: Viikilä P, Parkkila S, Kivelä AJ and Haglund C participated in the design of the study; Clinical and survival data were collected by Koskensalo S and Haglund C; Haglund C collected samples of this study and constructed tissue microarrays; Immunohistochemical staining and light microscopy was performed by Viikilä P; Waheed A, Sly WS, Pastorek J, Pastorekova S and Parkkila S produced and characterized the primary antibodies; Statistical analysis was done by Mustonen H; Viikilä P drafted the first version of the manuscript; all authors were involved in the writing process, read, and approved the final manuscript.
Telephone: +358-408-275235
Supported by the Sigrid Jusélius Foundation, the Academy of Finland, the Medical Research Funds of Tampere University Hospital and Helsinki University Hospital, and Jane and Aatos Erkko Foundation.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v22.i36.8168